News | May 3, 1999

Tetrionics to Manufacture Psoriasis Steroid for Phenederm

Tetrionics Inc. (Madison, WI) will manufacture ST-630, an active pharmaceutical ingredient (API), for Penederm Inc. (Foster City, CA), a wholly owned subsidiary of Mylan Laboratories Inc. (Pittsburgh). ST-630 is a topically applied hexafluoronated steroid that is being developed to treat psoriasis. The API will be used in an upcoming human clinical study of approximately 60 patients.

According to Herb Paaren, VP of Tetrionics, the chemistry of introducing the hexafluoro grouping required developing a new synthetic approach. But despite these hindrances, Tetrionics manufactures ST-630 to purities greater than 99.5%. At the completion of a 20-step reaction, the compound is made crystalline.

Tetrionics, a privately owned company, produces bulk and lab-scale bioactive chemicals for large pharmaceutical and biotech companies.

For more information: Herb Paaren, Tetrionics Inc., 505 Science Drive, Suite C, Madison, WI 53711. Tel: 608-233-3115. Fax: 608-233-6873.